RNA Therapy for Pulmonary Hypertension: Mechanisms, Clinical Evidence, and Future Directions

Abstract

Pulmonary hypertension (PH) is a severe, progressive disorder characterized by elevated pulmonary arterial pressure and vascular resistance, leading to right heart failure and increased mortality. Despite advances in conventional pharmacotherapy, morbidity and mortality remain substantial, necessitating innovative approaches. RNA-based therapies, including antisense oligonucleotides, small interfering RNAs (siRNAs), and messenger RNA (mRNA) modifications, offer novel mechanisms to modulate gene expression underlying pulmonary vascular remodeling. This review explores the epidemiology, pathophysiology, risk factors, clinical features, diagnostic considerations, and therapeutic landscape of PH, with a focus on current evidence and future potential of RNA therapies. We summarize recent clinical and preclinical data, discuss guideline recommendations, and highlight practical implications for clinicians.

Introduction

Pulmonary hypertension is a heterogeneous disorder defined by a mean pulmonary arterial pressure ≥20 mmHg at rest, confirmed by right heart catheterization. The condition encompasses multiple etiologies, including idiopathic, heritable, and secondary forms, with pulmonary arterial hypertension (PAH) representing the most severe subset. The pathogenesis involves complex interactions among genetic, molecular, and environmental factors, resulting in pulmonary vascular remodeling, vasoconstriction, and thrombosis. Traditional therapies target vasodilation and symptom relief, but recent advances in molecular understanding have paved the way for RNA-based interventions. This article provides an in-depth review of RNA therapy for PH, examining its mechanistic rationale, clinical evidence, and translational challenges.

Epidemiology / Disease Burden

PH affects an estimated 1% of the global population, increasing to 10% among individuals over 65 years. PAH is rarer, with a prevalence around 15-50 cases per million adults. The disease imposes a significant healthcare burden due to frequent hospitalizations, progressive disability, and premature mortality. Despite improved survival with combination therapies, five-year mortality for PAH remains approximately 35-40%. Delayed diagnosis, limited access to advanced therapies, and lack of curative options contribute to the high morbidity and mortality, underscoring the urgent need for novel disease-modifying treatments.

Pathophysiology

The pathobiology of PH is multifactorial, involving endothelial dysfunction, smooth muscle proliferation, inflammation, and thrombosis. Key molecular pathways include dysregulated bone morphogenetic protein receptor type 2 (BMPR2) signaling, enhanced endothelin-1 and serotonin activity, reduced nitric oxide (NO) bioavailability, and upregulated growth factors such as platelet-derived growth factor (PDGF). Recent omics studies have identified aberrant RNA expression profiles in pulmonary vascular cells, implicating microRNAs, long noncoding RNAs, and alternative splicing events in the disease process. These findings provide the mechanistic foundation for RNA-targeted therapies.

Risk Factors

Major risk factors for PH include heritable genetic mutations (e.g., BMPR2, ALK1, ENG), connective tissue diseases, congenital heart disease, portal hypertension, HIV infection, and exposure to anorexigens or methamphetamines. Environmental and epigenetic modulators, such as hypoxia, inflammation, and oxidative stress, further influence disease susceptibility and progression. Identifying high-risk individuals through genetic screening and biomarker profiling can facilitate early intervention and personalized therapy.

Clinical Features

PH typically presents with nonspecific symptoms, including exertional dyspnea, fatigue, chest pain, syncope, and peripheral edema. As the disease progresses, signs of right ventricular dysfunction and heart failure predominate. Physical findings may include a loud P2, right ventricular heave, jugular venous distension, hepatomegaly, and ascites. Noninvasive imaging (echocardiography) and biomarkers (NT-proBNP, troponin) aid in diagnosis and risk stratification, but definitive diagnosis requires invasive hemodynamic assessment.

Diagnosis

Diagnostic evaluation involves a structured approach to confirm PH, determine etiology, and assess severity. Transthoracic echocardiography is the initial screening tool, providing estimates of pulmonary artery pressure and right heart function. Laboratory tests evaluate for secondary causes (e.g., connective tissue disease, liver dysfunction, HIV). High-resolution computed tomography and ventilation-perfusion scans exclude parenchymal lung disease and chronic thromboembolic PH. Right heart catheterization remains the gold standard for definitive diagnosis and hemodynamic characterization. Genetic testing may be indicated in familial or idiopathic cases. Early and accurate diagnosis is critical for optimizing outcomes.

Treatment & Management

Standard management of PH includes supportive measures (oxygen, diuretics, anticoagulation) and targeted pharmacotherapies. Mainstay drugs comprise prostacyclin analogues (epoprostenol, treprostinil), endothelin receptor antagonists (bosentan, ambrisentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil), and soluble guanylate cyclase stimulators (riociguat). Combination regimens improve functional status and delay clinical worsening. Lung transplantation remains an option for advanced, refractory cases. However, current treatments do not reverse vascular remodeling or address underlying genetic drivers, highlighting the need for innovative molecular therapies such as RNA-based approaches.

Recent Advances / Emerging Therapies

RNA therapy offers a precision medicine approach to PH by selectively modulating gene expression implicated in pathogenesis. Preclinical studies have demonstrated the efficacy of antisense oligonucleotides (ASOs) targeting mutant BMPR2 transcripts, restoring receptor function and attenuating vascular remodeling. Small interfering RNAs (siRNAs) silencing overexpressed PDGF, endothelin-1, and serotonin transporter genes have shown promise in animal models, reducing pulmonary pressures and improving survival. Messenger RNA (mRNA) therapies encoding functional proteins (e.g., BMPR2, eNOS) are in early development. Delivery systems, such as lipid nanoparticles and inhaled formulations, enhance tissue specificity and minimize off-target effects. Several phase I/II trials are underway to evaluate safety, pharmacokinetics, and preliminary efficacy of RNA therapeutics in PH patients.

Guideline Recommendations

Current clinical guidelines (ESC/ERS 2022, CHEST 2021) recommend a multidisciplinary approach, emphasizing early diagnosis, individualized risk assessment, and combination pharmacotherapy. While RNA therapies are not yet integrated into routine clinical practice, ongoing clinical trials are closely monitored. Guidelines recognize the potential of gene- and RNA-targeted interventions, encouraging enrollment in research studies and biobanking for future precision medicine applications. The future incorporation of RNA therapy will depend on robust efficacy, safety, and cost-effectiveness data from well-designed trials.

Conclusion

RNA therapy represents a transformative frontier in the management of pulmonary hypertension, offering the possibility of directly addressing molecular drivers of disease. Preliminary clinical and preclinical evidence suggests efficacy in modulating pathogenic gene expression and reversing vascular remodeling. While challenges remain regarding delivery, immunogenicity, and long-term effects, the rapid progress in RNA therapeutics heralds a new era of precision medicine for PH. Continued research, multidisciplinary collaboration, and integration of molecular diagnostics will be essential to realize the full therapeutic potential of RNA-based interventions in pulmonary hypertension.